A comparison of genetically matched cell lines reveals the equivalence of human iPSCs and ESCs.
- Authors
- Choi, Jiho; Lee, Soohyun; Mallard, William; Clement, Kendell; Tagliazucchi, Guidantonio Malagoli; Lim, Hotae; Choi, In Young; Ferrari, Francesco; Tsankov, Alexander M; Pop, Ramona; Lee, Gabsang; Rinn, John L; Meissner, Alexander; Park, Peter J; Hochedlinger, Konrad
- Year
- 2015
- Journal
- Nature biotechnology
- PMID
- 26501951
- DOI
- 10.1038/nbt.3388
- PMCID
- PMC4847940
The equivalence of human induced pluripotent stem cells (hiPSCs) and human embryonic stem cells (hESCs) remains controversial. Here we use genetically matched hESC and hiPSC lines to assess the contribution of cellular origin (hESC vs. hiPSC), the Sendai virus (SeV) reprogramming method and genetic background to transcriptional and DNA methylation patterns while controlling for cell line clonality and sex. We find that transcriptional and epigenetic variation originating from genetic background dominates over variation due to cellular origin or SeV infection. Moreover, the 49 differentially expressed genes we detect between genetically matched hESCs and hiPSCs neither predict functional outcome nor distinguish an independently derived, larger set of unmatched hESC and hiPSC lines. We conclude that hESCs and hiPSCs are molecularly and functionally equivalent and cannot be distinguished by a consistent gene expression signature. Our data further imply that genetic background variation is a major confounding factor for transcriptional and epigenetic comparisons of pluripotent cell lines, explaining some of the previously observed differences between genetically unmatched hESCs and hiPSCs.
Generation of genetically matched hESCs and hiPSCs(A) Schematic for the generation of genetically matched hESC and hiPSC lines. (B) Overview of HUES2 and HUES3 derivatives used for RNA-sequencing. (C) Top panel shows bright images of hESC subclones, in vitro-differentiated fibroblasts, whereas the bottom panel shows hiPSC lines stained for alkaline phosphatase activity or OCT4 expression. Co-staining with DAPI confirmed nuclear expression of OCT4 (inset). (D) Heatmaps depicting DNA methylation (left) and gene expression (right) levels of key fibroblast-associated and pluripotency-associated genes in isogenic hESCs, in vitro-differentiated fibroblasts and derivative hiPSCs.
Influence of viral infection and genetic background on transcriptional patterns in isogenic hESCs and hiPSCs(A) Representative bright field (top) and fluorescence (bottom) images of the hESC GFP12 line at passage 2, 10, and 20 after SeV-GFP infection. (B) Expression levels of 63 genes that were identified to be significantly different between 3 biological replicates of hESC GFP and 3 biological replicates of hESC SC lines within each of the two genetic backgrounds (FDR<0.01 and fold change >2 or <0.5; see details in the Methods section). Green and grey boxes indicate the expression ranges for each differentially regulated gene in 6 hESC GFP and 6 hESC SC lines, respectively. TPM; transcripts per million. (C) Heatmap and dendrogram separating all isogenic hESC lines based on the 63 DEGs shown from Fig. 2B. hESC SC lines, dark blue; hESC GFP lines, light blue. (D) Heatmap and dendrogram for all isogenic hESC and hiPSC lines based on pairwise Pearson correlation (r) of global gene expression levels (log-scaled). hiPSC lines, red; hESC lines, blue.
Differentially expressed genes (DEGs) between isogenic hESC and hiPSC lines(a) Venn diagram showing the number of genes consistently up- or down- regulated in 3 biological replicate hiPSC lines when compared to 3 biological replicate hESC GFP lines from the same genetic background. (FDR<0.01 and fold change <2 or <1/2, see details in the Methods section). (B) Heatmap and dendrogram for all isogenic hESC and hiPSC lines based on the 49 differentially expressed genes (DEGs) that were common between the HUES2 and HUES3 backgrounds, using hierarchical clustering based on row-scaled expression levels. hiPSC lines, red; hESC lines, blue. (C) Box plot of 6 hESC GFP lines, 6 hiPSC lines, and parental fibroblasts for the 49 DEGs. Red and blue boxes indicate the expression ranges of each gene in hiPSC and hESC GFP lines, respectively. Diamonds and crosses indicate the expression levels of each gene in parental fibroblasts derived from HUES2 and HUES3 backgrounds, respectively. Genes are ordered by Studentβs t-test p-value between the 6 hiPSC and 6 hESC GFP lines. Red arrows depict genes discussed in main text. (D) RNA-seq read density of hESC GFP and hiPSC lines for OCT4, LDHA, SLC2A1, and CDX2. (E) Expression levels of OCT4, LDHA, SLC2A1, and CDX2 by qPCR in hESC GFP and hiPSC lines, normalized to ACTB (n=6). Studentβs t-test *, p<0.05; **, p<0.01. Mean Β± s.d. (F) Lactate production levels (left) and glucose uptake levels (right) of hESC GFP (blue) and hiPSC lines (red). Shown are data from three biological replicates for lactate assay (6 technical replicates) and from six biological replicates for glucose uptake assay (p>0.05 for both assays). Mean Β± s.d. (G) Representative Western blot for LDHA levels in hESC GFP (blue) and hiPSC (red) lines.
Dysregulation of genes in a subset of hiPSC lines(A) Heatmap of the 8 inconsistently differentially expressed genes (iDEGs) for all isogenic hESCs and hiPSC lines (as defined in Supplementary Fig. 3C) within each of the two genetic backgrounds at FDR<0.01 and fold change <2 or <0.5. hiPSC lines, red; hESC lines, blue. (B) Genome browser images of IRX2 and DPP10 RNA-seq reads in hESC GFP and hiPSC lines. (C) Expression levels of IRX2 and DPP10 by qPCR in each hESC GFP and hiPSC line, normalized to ACTB. Brown bars indicate hiPSC lines that have undergone aberrant silencing of IRX2 and DPP10. (D) Schematic for neural induction using the combination of SB431542, an ALK inhibitor, and LDN-193189, a BMP inhibitor. (E) Fold change of the neural markers NESTIN, SOX1, PAX6, and FOXG1 by qPCR in hESC GFP and hiPSC lines relative to the hESC GFP5 line. Brown bars indicate the hiPSC lines that have undergone transcriptional silencing of IRX2 and DPP10. Results are shown from three independent experiments. Mean Β± s.d. (F) Immunofluorescence staining of PAX6 (green) and SOX1 (red) indicates neural differentiation at day 6 in hESC GFP and hiPSC lines. DAPI (blue). (G) Scorecard assay of embryoid bodies (EBs) derived from isogenic hESC and hiPSC lines. Heatmap and dendrogram for these EBs based on the expression levels of the indicated developmental genes.
Analysis of previously reported gene expression differences and role of genetic background(A) Dendrogram and heatmap for unmatched hESC (blue) and hiPSC (red) lines based on pairwise Pearson correlation (r) on global gene expression levels (log- scaled). (B) Dendrogram based on the 49 DEGs identified using isogenic lines in Fig. 3C for all unmatched hESC (blue) and hiPSC (red) lines. Note the lack of clustering. (D) Venn diagram of differentially expressed genes between hESCs and hiPSCs identified in this study and previous reports utilizing unmatched hESCs and hiPSCs. Overlapping genes between DEGs from independent reprogramming studies are indicated by arrows. (D) Dendrogram of isogenic hESC and hiPSC lines using the differentially expressed genes identified by Phanstiel et al.10 (left panel) and dendrogram of hESC and hiPSC lines from Phanstiel et al. using HUES2 vs. HUES3-specific DEGs as discussed in the main text (right). hiPSC lines, red; hESC lines, blue. (E) Dendrogram and heatmap of isogenic hESC (blue) and hiPSC (red) lines based on HUES2 vs. HUES3-specific DEGs. (F) Transcriptional variation of different gene sets across unmatched hESC and hiPSC lines reported by Bock et al. Boxplots show mean absolute deviation (MAD) among hiPSCs and hESCs when considering indicated DEG sets. Note that HUES2 vs HUES3-specific DEGs show the greatest variation. A one-tailed Wilcoxon ranksum test was performed between each set of DEGs and all genes.
No entities extracted from this document yet.
No uploaded files.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Biomimetic Multifunctional Scaffolds for Osteochondral Regeneration: Bridging Material Design and Functional Integration. | Zhong J et al. | β | 2026 | β |
| Clinical translational research on stem cell products: prospects and challenges. | Chen S et al. | β | 2026 | β |
| Serum coating enables feeder-free culture of naive human pluripotent stem cells preserving developmental potential. | Rossignoli G et al. | β | 2026 | β |
| Allelic bias contributes to heterogeneous phenotypes of NK cell deficiency. | Seo S et al. | β | 2025 | β |
| Combine the wet and dry ingredients: Mixing experimental and computational models for a deeper understanding of stem cell-derived cardiomyocytes. | Yang J et al. | β | 2025 | β |
| Generation and characterization of human-induced pluripotent stem cell lines from patients with autism spectrum disorder and SCN2A variants. | Santos JLS et al. | β | 2025 | β |
| Induced Pluripotent (iPSC) and Mesenchymal (MSC) Stem Cells for In Vitro Disease Modeling and Regenerative Medicine. | Panferov E et al. | β | 2025 | β |
| KLF7 is a general inducer of human pluripotency. | Arboit M et al. | β | 2025 | β |
| Pluripotent cell states and fates in human embryo models. | Sozen B et al. | β | 2025 | β |
| Pre-clinical safety and efficacy of human induced pluripotent stem cell-derived products for autologous cell therapy in Parkinson's disease. | Jeon J et al. | β | 2025 | β |
| Production of live monkeys and their genetically matched embryonic stem cells from single embryos. | Si C et al. | β | 2025 | β |
| Progression of differentiation of iPSCs into specific subtypes of neurons. | Wang J et al. | β | 2025 | β |
| Topological data analysis of pattern formation of human induced pluripotent stem cell colonies. | Hartsock I et al. | β | 2025 | β |
| A Novel Stem Cell Model to Study Preeclampsia Endothelial Dysfunction. | Wu Y et al. | β | 2024 | β |
| Epigenetic and Transcriptional Shifts in Human Neural Stem Cells after Reprogramming into Induced Pluripotent Stem Cells and Subsequent Redifferentiation. | Haubenreich C et al. | β | 2024 | β |
| hESC- and hiPSC-derived Schwann cells are molecularly comparable and functionally equivalent. | Moss KR et al. | β | 2024 | β |
| Incomplete reprogramming of DNA replication timing in induced pluripotent stem cells. | Edwards MM et al. | β | 2024 | β |
| Individual variation in the emergence of anterior-to-posterior neural fates from human pluripotent stem cells. | Kim SK et al. | β | 2024 | β |
| Manipulating cell fate through reprogramming: approaches and applications. | Yagi M et al. | β | 2024 | β |
| Neuronal Cell Differentiation of iPSCs for the Clinical Treatment of Neurological Diseases. | Lee DH et al. | β | 2024 | β |
| Terminal Ξ±1,2-fucosylation of glycosphingolipids by FUT1 is a key regulator in early cell-fate decisions. | Chen S et al. | β | 2024 | β |
| "Time Is out of Joint" in Pluripotent Stem Cells: How and Why. | Agriesti F et al. | β | 2024 | β |
| Application of Human Stem Cells to Model Genetic Sensorineural Hearing Loss and Meniere Disease. | Lamolda M et al. | β | 2023 | β |
| Arouse potential stemness: Intrinsic and acquired stem cell therapeutic strategies for advanced liver diseases. | Song Y et al. | β | 2023 | β |
| A treatment within sight: challenges in the development of stem cell-derived photoreceptor therapies for retinal degenerative diseases. | Beaver D et al. | β | 2023 | β |
| CRISPR-Cas12a-integrated transgenes in genomic safe harbors retain high expression in human hematopoietic iPSC-derived lineages and primary cells. | Vlassis A et al. | β | 2023 | β |
| Generating universal chimeric antigen receptor expressing cell products from induced pluripotent stem cells: beyond the autologous CAR-T cells. | Deng X et al. | β | 2023 | β |
| Human cortical spheroids with a high diversity of innately developing brain cell types. | De Kleijn KMA et al. | β | 2023 | β |
| Immune cells and RBCs derived from human induced pluripotent stem cells: method, progress, prospective challenges. | Jiang JH et al. | β | 2023 | β |
| iPSC-derived cells lack immune tolerance to autologous NK-cells due to imbalance in ligands for activating and inhibitory NK-cell receptors. | Bogomiakova ME et al. | β | 2023 | β |
| iPSC Models of Leukemia Come of Age. | Doulatov S | β | 2023 | β |
| Transient naive reprogramming corrects hiPS cells functionally and epigenetically. | Buckberry S et al. | β | 2023 | β |
| Transition from Animal-Based to Human Induced Pluripotent Stem Cells (iPSCs)-Based Models of Neurodevelopmental Disorders: Opportunities and Challenges. | Guerreiro S et al. | β | 2023 | β |
| Wnt signaling and the regulation of pluripotency. | Sonavane P et al. | β | 2023 | β |
| Deconvoluting the Cells of the Human Heart with iPSC Technology: Cell Types, Protocols, and Uses. | Yu B et al. | β | 2022 | β |
| Determining epigenetic memory in kidney proximal tubule cell derived induced pluripotent stem cells using a quadruple transgenic reprogrammable mouse. | Khelifi G et al. | β | 2022 | β |
| Generation of CD34<sup>+</sup>CD43<sup>+</sup> Hematopoietic Progenitors to Induce Thymocytes from Human Pluripotent Stem Cells. | Flippe L et al. | β | 2022 | β |
| HOX genes in stem cells: Maintaining cellular identity and regulation of differentiation. | Steens J et al. | β | 2022 | β |
| Human Pluripotent Stem Cells for High-Throughput Drug Screening and Characterization of Small Molecules. | Ryu S et al. | β | 2022 | β |
| Huntington's disease iPSC models-using human patient cells to understand the pathology caused by expanded CAG repeats. | Kaye J et al. | β | 2022 | β |
| Induced Pluripotent Stem Cells for Treatment of Alzheimer's and Parkinson's Diseases. | Yefroyev DA et al. | β | 2022 | β |
| Quantifying Chromosome Structural Reorganizations during Differentiation, Reprogramming, and Transdifferentiation. | Chu X et al. | β | 2022 | β |
| Recurrent RNA edits in human preimplantation potentially enhance maternal mRNA clearance. | Ding Y et al. | β | 2022 | β |
| Stem Cell-Based Embryo Models: En Route to a Programmable Future. | Chen Y et al. | β | 2022 | β |
| The Defects of Epigenetic Reprogramming in Dox-Dependent Porcine-iPSCs. | Jiang A et al. | β | 2022 | β |
| A comprehensive library of human transcription factors for cell fate engineering. | Ng AHM et al. | β | 2021 | β |
| Animal and cellular models of microphthalmia. | Harding P et al. | β | 2021 | β |
| Complex biology of constitutional ring chromosomes structure and (in)stability revealed by somatic cell reprogramming. | Nikitina TV et al. | β | 2021 | β |
| Convergent genomic and pharmacological evidence of PI3K/GSK3 signaling alterations in neurons from schizophrenia patients. | Stertz L et al. | β | 2021 | β |
| Developing nociceptor-selective treatments for acute and chronic pain. | Jayakar S et al. | β | 2021 | β |
| Human Pluripotent Stem Cells to Model Islet Defects in Diabetes. | Balboa D et al. | β | 2021 | β |
| Human stem cell-based models for studying host-pathogen interactions. | Pellegrino E et al. | β | 2021 | β |
| Identification of an epigenetic signature in human induced pluripotent stem cells using a linear machine learning model. | Nishino K et al. | β | 2021 | β |
| Identification of Differentially Expressed Human Endogenous Retrovirus Families in Human Leukemia and Lymphoma Cell Lines and Stem Cells. | Engel K et al. | β | 2021 | β |
| Identification of rare and common regulatory variants in pluripotent cells using population-scale transcriptomics. | Bonder MJ et al. | β | 2021 | β |
| Induced pluripotent stem cell models of myeloid malignancies and clonal evolution. | Reilly A et al. | β | 2021 | β |
| Induced pluripotent stem cell technology: trends in molecular biology, from genetics to epigenetics. | Maali A et al. | β | 2021 | β |
| Induced Tissue-Specific Stem Cells (iTSCs): Their Generation and Possible Use in Regenerative Medicine. | Saitoh I et al. | β | 2021 | β |
| Inherent genomic properties underlie the epigenomic heterogeneity of human induced pluripotent stem cells. | Yokobayashi S et al. | β | 2021 | β |
| iPSC Preparation and Epigenetic Memory: Does the Tissue Origin Matter? | Scesa G et al. | β | 2021 | β |
| Modeling the Human Body on Microfluidic Chips. | Jalili-Firoozinezhad S et al. | β | 2021 | β |
| Pancreatic Extracellular Matrix/Alginate Hydrogels Provide a Supportive Microenvironment for Insulin-Producing Cells. | Wang D et al. | β | 2021 | β |
| Patient derived stem cells for discovery and validation of novel pathogenic variants in inherited retinal disease. | Mullin NK et al. | β | 2021 | β |
| Stem-cell-based embryo models for fundamental research and translation. | Fu J et al. | β | 2021 | β |
| The Potential of Induced Pluripotent Stem Cells to Advance the Treatment of Pancreatic Ductal Adenocarcinoma. | Krog RT et al. | β | 2021 | β |
| The Potential Properties of Natural Compounds in Cardiac Stem Cell Activation: Their Role in Myocardial Regeneration. | Carresi C et al. | β | 2021 | β |
| Three-dimensional chromatin organization in cardiac development and disease. | Bertero A et al. | β | 2021 | β |
| Addressing Variability and Heterogeneity of Induced Pluripotent Stem Cell-Derived Cardiomyocytes. | Biendarra-Tiegs SM et al. | β | 2020 | β |
| "Betwixt Mine Eye and Heart a League Is Took": The Progress of Induced Pluripotent Stem-Cell-Based Models of Dystrophin-Associated Cardiomyopathy. | Rovina D et al. | β | 2020 | β |
| Cholinergic-like neurons carrying PSEN1 E280A mutation from familial Alzheimer's disease reveal intraneuronal sAPPΞ² fragments accumulation, hyperphosphorylation of TAU, oxidative stress, apoptosis and Ca2+ dysregulation: Therapeutic implications. | Soto-Mercado V et al. | β | 2020 | β |
| Dissecting transcriptomic signatures of neuronal differentiation and maturation using iPSCs. | Burke EE et al. | β | 2020 | β |
| Distinct Processing of lncRNAs Contributes to Non-conserved Functions in Stem Cells. | Guo CJ et al. | β | 2020 | β |
| Epigenetic Memory: Lessons From iPS Cells Derived From Human Ξ² Cells. | Efrat S | β | 2020 | β |
| Human Induced Pluripotent Stem Cell Models of Neurodegenerative Disorders for Studying the Biomedical Implications of Autophagy. | Seranova E et al. | β | 2020 | β |
| Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer. | Zhang D et al. | β | 2020 | β |
| Mapping the Effects of Genetic Variation on Chromatin State and Gene Expression Reveals Loci That Control Ground State Pluripotency. | Skelly DA et al. | β | 2020 | β |
| Microscopic Chromosomal Structural and Dynamical Origin of Cell Differentiation and Reprogramming. | Chu X et al. | β | 2020 | β |
| Motor Neuron Generation from iPSCs from Identical Twins Discordant for Amyotrophic Lateral Sclerosis. | Seminary ER et al. | β | 2020 | β |
| Pluripotent Stem Cell-Based Cell Therapy-Promise and Challenges. | Yamanaka S | β | 2020 | β |
| Pluripotent stem cells with low differentiation potential contain incompletely reprogrammed DNA replication. | Paniza T et al. | β | 2020 | β |
| Recent progress in translational engineered in vitro models of the central nervous system. | Nikolakopoulou P et al. | β | 2020 | β |
| Resolving Neurodevelopmental and Vision Disorders Using Organoid Single-Cell Multi-omics. | Brancati G et al. | β | 2020 | β |
| RNA-Seq analysis reveals pluripotency-associated genes and their interaction networks in human embryonic stem cells. | Ghosh A et al. | β | 2020 | β |
| The Dynamic Proteome of Oligodendrocyte Lineage Differentiation Features Planar Cell Polarity and Macroautophagy Pathways. | Pooyan P et al. | β | 2020 | β |
| The Master Regulator Protein BAZ2B Can Reprogram Human Hematopoietic Lineage-Committed Progenitors into a Multipotent State. | Arumugam K et al. | β | 2020 | β |
| The Mechanism of Programmed Aging: The Way to Create a Real Remedy for Senescence. | Trubitsyn AG | β | 2020 | β |
| The Use of Induced Pluripotent Stem Cells as a Model for Developmental Eye Disorders. | Eintracht J et al. | β | 2020 | β |
| Adult Stem Cells. | Prentice DA | β | 2019 | β |
| Characterization of iPSCs derived from low grade gliomas revealed early regional chromosomal amplifications during gliomagenesis. | Liu Z et al. | β | 2019 | β |
| Conserved regulation of RNA processing in somatic cell reprogramming. | Kanitz A et al. | β | 2019 | β |
| De Novo DNA Methylation at Imprinted Loci during Reprogramming intoΒ Naive and Primed Pluripotency. | Yagi M et al. | β | 2019 | β |
| Direct transdifferentiation of human Wharton's jelly mesenchymal stromal cells into cholinergic-like neurons. | Mendivil-Perez M et al. | β | 2019 | β |
| DRUGPATH - a novel bioinformatic approach identifies DNA-damage pathway as a regulator of size maintenance in human ESCs and iPSCs. | Kovacic B et al. | β | 2019 | β |
| Epigenetic Analysis in Human Neurons: Considerations for Disease Modeling in PD. | de Boni L et al. | β | 2019 | β |
| Human Circadian Molecular Oscillation Development Using Induced Pluripotent Stem Cells. | Umemura Y et al. | β | 2019 | β |
| Improving homology-directed repair efficiency in human stem cells. | Skarnes WC et al. | β | 2019 | β |
| Modeling Disease with Human Inducible Pluripotent Stem Cells. | Grandy R et al. | β | 2019 | β |
| Modeling myeloid malignancies with patient-derived iPSCs. | Papapetrou EP | β | 2019 | β |
| Next-generation disease modeling with direct conversion: a new path to old neurons. | Traxler L et al. | β | 2019 | β |
| Polybenzyl Glutamate Biocompatible Scaffold Promotes the Efficiency of Retinal Differentiation toward Retinal Ganglion Cell Lineage from Human-Induced Pluripotent Stem Cells. | Chen TC et al. | β | 2019 | β |
| Reproducibility and staging of 3D human retinal organoids across multiple pluripotent stem cell lines. | Capowski EE et al. | β | 2019 | β |
| Systems-Wide Approaches in Induced Pluripotent Stem Cell Models. | Lau E et al. | β | 2019 | β |
| The Challenge of Bringing iPSCs to the Patient. | OrtuΓ±o-Costela MDC et al. | β | 2019 | β |
| The Contribution of Pluripotent Stem Cell (PSC)-Based Models to the Study of Fragile X Syndrome (FXS). | Abu Diab M et al. | β | 2019 | β |
| The interplay of chromatin and transcription factors during cell fate transitions in development and reprogramming. | PeΓ±alosa-Ruiz G et al. | β | 2019 | β |
| Bringing Induced Pluripotent Stem Cell Technology to the Bedside. | Karagiannis P et al. | β | 2018 | β |
| Cellular reprogramming: A new way to understand aging mechanisms. | Yener Ilce B et al. | β | 2018 | β |
| Characterization of companion animal pluripotent stem cells. | Paterson YZ et al. | β | 2018 | β |
| DNA methylation alterations in iPSC- and hESC-derived neurons: potential implications for neurological disease modeling. | de Boni L et al. | β | 2018 | β |
| Efficient generation of transgene- and feeder-free induced pluripotent stem cells from human dental mesenchymal stem cells and their chemically defined differentiation into cardiomyocytes. | Tan X et al. | β | 2018 | β |
| Elixir of Life: Thwarting Aging With Regenerative Reprogramming. | Beyret E et al. | β | 2018 | β |
| Epigenetic-scale comparison of human iPSCs generated by retrovirus, Sendai virus or episomal vectors. | Nishino K et al. | β | 2018 | β |
| From the Psychiatrist's Couch to Induced Pluripotent Stem Cells: Bipolar Disease in a Dish. | Hoffmann A et al. | β | 2018 | β |
| Generation of Human Induced Pluripotent Stem Cells Using a Defined, Feeder-Free Reprogramming System. | Park S et al. | β | 2018 | β |
| Genetic and epigenetic factors which modulate differentiation propensity in human pluripotent stem cells. | Keller A et al. | β | 2018 | β |
| Genetics of Alcohol Use Disorder: A Role for Induced Pluripotent Stem Cells? | Prytkova I et al. | β | 2018 | β |
| Hierarchical Design of Tissue Regenerative Constructs. | Rose JC et al. | β | 2018 | β |
| Humanity in a Dish: Population Genetics with iPSCs. | Warren CR et al. | β | 2018 | β |
| Impact of regulatory variation across human iPSCs and differentiated cells. | Banovich NE et al. | β | 2018 | β |
| Induced pluripotent stem cells derived from human amnion in chemically defined conditions. | Slamecka J et al. | β | 2018 | β |
| Induced Pluripotent Stem Cells for Cardiovascular Disease Modeling and Precision Medicine: A Scientific Statement From the American Heart Association. | Musunuru K et al. | β | 2018 | β |
| Induced pluripotent stem cells for treating cystic fibrosis: State of the science. | Pollard BS et al. | β | 2018 | β |
| Induced Tissue-Specific Stem Cells and Epigenetic Memory in Induced Pluripotent Stem Cells. | Noguchi H et al. | β | 2018 | β |
| iPSC modeling of severe aplastic anemia reveals impaired differentiation and telomere shortening in blood progenitors. | Melguizo-Sanchis D et al. | β | 2018 | β |
| JIP2 haploinsufficiency contributes to neurodevelopmental abnormalities in human pluripotent stem cell-derived neural progenitors and cortical neurons. | Roessler R et al. | β | 2018 | β |
| Modeling Parkinson's Disease Using Patient-specific Induced Pluripotent Stem Cells. | Li H et al. | β | 2018 | β |
| Preserving self-renewal of porcine pluripotent stem cells in serum-free 3i culture condition and independent of LIF and b-FGF cytokines. | Ma Y et al. | β | 2018 | β |
| Reduced MEK inhibition preserves genomic stability in naive human embryonic stem cells. | Di Stefano B et al. | β | 2018 | β |
| Sporadic Parkinson's disease derived neuronal cells show disease-specific mRNA and small RNA signatures with abundant deregulation of piRNAs. | Schulze M et al. | β | 2018 | β |
| The Histone Variant MacroH2A Blocks Cellular Reprogramming by Inhibiting Mesenchymal-to-Epithelial Transition. | Pliatska M et al. | β | 2018 | β |
| The role of connexins during early embryonic development: pluripotent stem cells, gene editing, and artificial embryonic tissues as tools to close the knowledge gap. | WΓΆrsdΓΆrfer P et al. | β | 2018 | β |
| The Role of microRNAs in Embryonic and Induced Pluripotency. | Beh-Pajooh A et al. | β | 2018 | β |
| The role of the reprogramming method and pluripotency state in gamete differentiation from patient-specific human pluripotent stem cells. | Mishra S et al. | β | 2018 | β |
| The state of the art in stem cell biology and regenerative medicine: the end of the beginning. | Snyder EY | β | 2018 | β |
| Understanding the role of steroids in typical and atypical brain development: Advantages of using a "brain in a dish" approach. | Adhya D et al. | β | 2018 | β |
| Urine-derived cells provide a readily accessible cell type for feeder-free mRNA reprogramming. | Gaignerie A et al. | β | 2018 | β |
| Who Will Win: Induced Pluripotent Stem Cells Versus Embryonic Stem Cells for Ξ² Cell Replacement and Diabetes Disease Modeling? | Jacobson EF et al. | β | 2018 | β |
| Aberrant DNA Methylation in Human iPSCs Associates with MYC-Binding Motifs in a Clone-Specific Manner Independent of Genetics. | Panopoulos AD et al. | β | 2017 | β |
| An Activating STAT3 Mutation Causes Neonatal Diabetes through Premature Induction of Pancreatic Differentiation. | SaarimΓ€ki-Vire J et al. | β | 2017 | β |
| Analysis of Transcriptional Variability in a Large Human iPSC Library Reveals Genetic and Non-genetic Determinants of Heterogeneity. | Carcamo-Orive I et al. | β | 2017 | β |
| Capturing Human NaΓ―ve Pluripotency in the Embryo and in the Dish. | Zimmerlin L et al. | β | 2017 | β |
| Cell Type-Specific Chromatin Signatures Underline Regulatory DNA Elements in Human Induced Pluripotent Stem Cells and Somatic Cells. | Zhao MT et al. | β | 2017 | β |
| Characterization of microRNAs expression profiles in human dental-derived pluripotent stem cells. | Tan X et al. | β | 2017 | β |
| Common genetic variation drives molecular heterogeneity in human iPSCs. | Kilpinen H et al. | β | 2017 | β |
| Correction of Hirschsprung-Associated Mutations in Human Induced Pluripotent Stem Cells Via Clustered Regularly Interspaced Short Palindromic Repeats/Cas9, Restores NeuralΒ Crest Cell Function. | Lai FP et al. | β | 2017 | β |
| Differentiation-Defective Human Induced Pluripotent Stem Cells RevealΒ Strengths and Limitations of the Teratoma Assay and InΒ Vitro Pluripotency Assays. | Bouma MJ et al. | β | 2017 | β |
| Divergent Levels of Marker Chromosomes in an hiPSC-Based Model ofΒ Psychosis. | Tcw J et al. | β | 2017 | β |
| DNA Damage in Stem Cells. | Vitale I et al. | β | 2017 | β |
| DNA methylation and transcriptional trajectories during human development and reprogramming of isogenic pluripotent stem cells. | Roost MS et al. | β | 2017 | β |
| Efficient production of trophoblast lineage cells from human induced pluripotent stem cells. | Kojima J et al. | β | 2017 | β |
| Epigenetic foundations of pluripotent stem cells that recapitulate in vivo pluripotency. | Yagi M et al. | β | 2017 | β |
| Friedreich's ataxia induced pluripotent stem cell-derived cardiomyocytes display electrophysiological abnormalities and calcium handling deficiency. | Crombie DE et al. | β | 2017 | β |
| Genetically unmatched human iPSC and ESC exhibit equivalent gene expression and neuronal differentiation potential. | Marei HE et al. | β | 2017 | β |
| Human induced pluripotent stem cells for modelling neurodevelopmental disorders. | Ardhanareeswaran K et al. | β | 2017 | β |
| iPSCORE: A Resource of 222 iPSC Lines Enabling Functional Characterization of Genetic Variation across a Variety of Cell Types. | Panopoulos AD et al. | β | 2017 | β |
| IRFinder: assessing the impact of intron retention on mammalian gene expression. | Middleton R et al. | β | 2017 | β |
| KATapulting toward Pluripotency and Cancer. | Hirsch CL et al. | β | 2017 | β |
| Kidney Organoids: A Translational Journey. | Morizane R et al. | β | 2017 | β |
| Large, Diverse Population Cohorts of hiPSCs and Derived Hepatocyte-like Cells Reveal Functional Genetic Variation at Blood Lipid-Associated Loci. | Pashos EE et al. | β | 2017 | β |
| Large-Scale Profiling Reveals the Influence of Genetic Variation on Gene Expression in Human Induced Pluripotent Stem Cells. | DeBoever C et al. | β | 2017 | β |
| Modeling schizophrenia pathogenesis using patient-derived induced pluripotent stem cells (iPSCs). | Noh H et al. | β | 2017 | β |
| Molecular and functional resemblance of differentiated cells derived from isogenic human iPSCs and SCNT-derived ESCs. | Zhao MT et al. | β | 2017 | β |
| Naked Mole Rat Induced Pluripotent Stem Cells and Their Contribution to Interspecific Chimera. | Lee SG et al. | β | 2017 | β |
| Overcoming barriers to reprogramming and differentiation in nonhuman primate induced pluripotent stem cells. | Hemmi JJ et al. | β | 2017 | β |
| Pluripotent stem cells to hepatocytes, the journey so far. | Palakkan AA et al. | β | 2017 | β |
| Protein profiling identified key chemokines that regulate the maintenance of human pluripotent stem cells. | Jiang Z et al. | β | 2017 | β |
| Reprogramming Methods Do Not Affect Gene Expression Profile of Human Induced Pluripotent Stem Cells. | Trevisan M et al. | β | 2017 | β |
| Roles of Diffusion Dynamics in Stem Cell Signaling and Three-Dimensional Tissue Development. | McMurtrey RJ | β | 2017 | β |
| Strategies for retinal cell generation from human pluripotent stem cells. | Weed LS et al. | β | 2017 | β |
| Ten years since the discovery of iPS cells: The current state of their clinical application. | Aznar J et al. | β | 2017 | β |
| Transcriptional signatures of schizophrenia in hiPSC-derived NPCs and neurons are concordant with post-mortem adult brains. | Hoffman GE et al. | β | 2017 | β |
| Transcriptomic and epigenomic differences in human induced pluripotent stem cells generated from six reprogramming methods. | Churko JM et al. | β | 2017 | β |
| Variability of human pluripotent stem cell lines. | Ortmann D et al. | β | 2017 | β |
| A decade of transcription factor-mediated reprogramming to pluripotency. | Takahashi K et al. | β | 2016 | β |
| Bioinformatic and Genomic Analyses of Cellular Reprogramming and Direct Lineage Conversion. | Kareta MS | β | 2016 | β |
| Capturing the ephemeral human pluripotent state. | Γvila-GonzΓ‘lez D et al. | β | 2016 | β |
| CGG Repeat-Induced FMR1 Silencing Depends on the Expansion Size in Human iPSCs and Neurons Carrying Unmethylated Full Mutations. | Brykczynska U et al. | β | 2016 | β |
| Dynamic stem cell states: naive to primed pluripotency in rodents and humans. | Weinberger L et al. | β | 2016 | β |
| Effects of cellular origin on differentiation of human induced pluripotent stem cell-derived endothelial cells. | Hu S et al. | β | 2016 | β |
| Human induced pluripotent stem cells: A disruptive innovation. | De Vos J et al. | β | 2016 | β |
| Human Induced Pluripotent Stem Cells as a Platform for Personalized and Precision Cardiovascular Medicine. | Matsa E et al. | β | 2016 | β |
| Induced pluripotent stem cells: at the heart of cardiovascular precision medicine. | Chen IY et al. | β | 2016 | β |
| Induced Pluripotent Stem Cell Therapies for Cervical Spinal Cord Injury. | Doulames VM et al. | β | 2016 | β |
| Is Transforming Stem Cells to Pancreatic Beta Cells Still the Holy Grail for Type 2 Diabetes? | Kahraman S et al. | β | 2016 | β |
| Modeling Fragile X Syndrome Using Human Pluripotent Stem Cells. | Mor-Shaked H et al. | β | 2016 | β |
| Modeling psychiatric disorders: from genomic findings to cellular phenotypes. | Falk A et al. | β | 2016 | β |
| Molecular Obstacles to Clinical Translation of iPSCs. | Tapia N et al. | β | 2016 | β |
| Patient-derived induced pluripotent stem cells in cancer research and precision oncology. | Papapetrou EP | β | 2016 | β |
| Peroxiredoxin-2 nitrosylation facilitates cardiomyogenesis of mouse embryonic stem cells via XBP-1s/PI3K pathway. | Wu B et al. | β | 2016 | β |
| Pluripotent stem cells as a model for embryonic patterning: From signaling dynamics to spatial organization in a dish. | Heemskerk I et al. | β | 2016 | β |
| Site-Specific Genome Engineering in Human Pluripotent Stem Cells. | Merkert S et al. | β | 2016 | β |
| Studying the pathophysiologic connection between cardiovascular and nervous systems using stem cells. | Coskun V et al. | β | 2016 | β |
| Transcriptome Profiling of Patient-Specific Human iPSC-Cardiomyocytes Predicts Individual Drug Safety and Efficacy Responses InΒ Vitro. | Matsa E et al. | β | 2016 | β |
| Translating Stem Cell Biology Into Drug Discovery. | SingeΓ§ I et al. | β | 2016 | β |
| Translation of Human-Induced PluripotentΒ Stem Cells: From Clinical Trial in a Dish to Precision Medicine. | Sayed N et al. | β | 2016 | β |
| Utility of Lymphoblastoid Cell Lines for Induced Pluripotent Stem Cell Generation. | Kumar S et al. | β | 2016 | β |
| Dynamic stem cell states: naΓ―ve to primed pluripotency in rodents and humans | Weinberger L et al. | β | 2015 | β |
| Pluripotent stem cells for disease modeling and drug screening: new perspectives for treatment of cystic fibrosis? | Martin U | β | 2015 | β |
| Putting induced pluripotent stem cells to the test. | Vallier L | β | 2015 | β |
| [Leukocyte count of puerperal sows]. | MΓ€de D et al. | β | 1996 | β |